H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fortress Biotech (FBIO) today and set a price target of $10.00. The company’s shares closed last Monday at $3.23.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.7% and a 54.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Fortress Biotech is a Strong Buy with an average price target of $8.00, implying a 166.7% upside from current levels. In a report issued on October 2, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.78 and a one-year low of $1.04. Currently, Fortress Biotech has an average volume of 1.44M.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.
